User:Mr. Ibrahem/Pacritinib
 | |
| Clinical data | |
|---|---|
| Trade names | Vonjo, Enpaxiq |
| Other names | SB1518 |
| AHFS/Drugs.com | Monograph |
| License data |
|
| Routes of administration | By mouth |
| Legal status | |
| Legal status | |
| Identifiers | |
| |
| Chemical and physical data | |
| Formula | C28H32N4O3 |
| Molar mass | 472.589 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Pacritinib, sold under the brand name Vonjo, is an medication used to treat myelofibrosis.[1] Specifically it is used in those with a platelet count less than 50 × 109/L in who it decreases the size of the spleen.[1] It is taken by mouth.[1]
Common side effects include diarrhea, low platelets, nausea, low hemoglobin, and swollen legs.[1] Other side effects may include bleeding, prolonged QT, deep vein thrombosis, cancer, and infection.[1] Use is not recommended in those with significant liver or kidney problems.[1] It is a kinase inhibitor that blocks the action of Janus kinase 2 (JAK2) and fms-like tyrosine kinase 3\CD135 (FLT3).[3]
Pacritinib was approved for medical use in the United States in 2022.[1] Its application for approval in Europe was withdrawn in 2017 due to concerns it worsened outcomes.[3] In the United States a month of medication costs about 23,000 USD as of 2022.[4]
References[edit]
- ^ a b c d e f g h i j k "Vonjo- pacritinib capsule". DailyMed. 7 March 2022. Archived from the original on 24 March 2022. Retrieved 24 March 2022.
- ^ "FDA approves drug for adults with rare form of bone marrow disorder". U.S. Food and Drug Administration. 1 March 2022. Archived from the original on 3 March 2022. Retrieved 3 March 2022.
This article incorporates text from this source, which is in the public domain.
- ^ a b "Enpaxiq: Withdrawal of the marketing authorisation application". Archived from the original on 4 August 2020. Retrieved 11 December 2022.
- ^ "Vonjo Prices, Coupons, Copay & Patient Assistance". Drugs.com. Retrieved 11 December 2022.
